Cabenuva

Chemical Namecabotegravir/rilpivirine
Dosage FormInjection (intramuscular; 600 mg/3mL, 400 mg/2mL)
Drug ClassAntivirals
SystemCardiovascular
CompanyViiv Healthcare
Approval Year2021

Indication

  • Indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Last updated on 1/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cabenuva (cabotegravir/rilpivirine) Prescribing Information2021Viiv Healthcare, Laval, Quebec